FITC标记的抑癌基因p16抗体-抗体-抗体-生物在线
上海沪震实业有限公司
FITC标记的抑癌基因p16抗体

FITC标记的抑癌基因p16抗体

商家询价

产品名称： FITC标记的抑癌基因p16抗体

英文名称： Anti-CDKN2A/p16-INK4a/FITC

产品编号： HZ-20656R-FITC

产品价格： null

产品产地： 中国/上海

品牌商标： HZbscience

更新时间： 2023-08-17T10:24:20

使用范围： ICC=1:50-200 IF=1:50-200

上海沪震实业有限公司
  • 联系人 : 鲍丽雯
  • 地址 : 上海市闵行区闵北路88弄1-30号第22幢AQ136室
  • 邮编 : 200612
  • 所在区域 : 上海
  • 电话 : 139****0749 点击查看
  • 传真 : 点击查看
  • 邮箱 : www.shzbio.net
  • 二维码 : 点击查看
进入展台

 Rabbit Anti-CDKN2A/p16-INK4a/FITC Conjugated antibody

FITC标记的抑癌基因p16抗体

 

英文名称 Anti-CDKN2A/p16-INK4a/FITC
中文名称 FITC标记的抑癌基因p16抗体
别    名 cyclin-dependent kinase inhibitor 2A; CDK4I; p16-INK4; p16-INK4a; cyclin-dependent kinase 4 inhibitor A; cyclin-dependent kinase inhibitor 2A, isoform 1; Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4); cell cycle inhibitor; cyclin-dependent kinase inhibitor 2a p16Ink4a; cell cycle regulator; cyclin-dependent kinase inhibitor 2a p19Arf; cyclin-dependent kinase inhibitor 2A, isoform 2; Cdkn2a; Arf; INK4A; MTS1; p16; p16Cdkn2a; p19ARF; CD2A1_HUMAN.  
规格价格 100ul/2980元 购买        大包装/询价
说 明 书 100ul  
研究领域 肿瘤  细胞生物  免疫学  信号转导  细胞凋亡  细胞周期蛋白  
抗体来源 Rabbit
克隆类型 Polyclonal
交叉反应 Human, 
产品应用 ICC=1:50-200 IF=1:50-200  
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量 17kDa
性    状 Lyophilized or Liquid
浓    度 2mg/1ml
免 疫 原 KLH conjugated synthetic peptide derived from human CDKN2A/p16-INK4a
亚    型 IgG
纯化方法 affinity purified by Protein A
储 存 液 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存条件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
产品介绍 background:
This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012]. 

Function:
Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein. 

Subunit:
Heterodimer with CDK4 or CDK6. Predominant p16 complexes contained CDK6. Interacts (isoforms 1,2 and 4) with CDK4 (both 'T-172'-phosphorylated and non-phosphorylated forms); the interaction inhibits cyclin D-CDK4 kinase activity. Interacts with ISCO2. 

Subcellular Location:
Cytoplasm. Nucleus.

Tissue Specificity:
Widely expressed but not detected in brain or skeletal muscle. Isoform 3 is pancreas-specific.

DISEASE:
ote=The association between cutaneous and uveal melanomas in some families suggests that mutations in CDKN2A may account for a proportion of uveal melanomas. However, CDKN2A mutations are rarely found in uveal melanoma patients. 
Defects in CDKN2A are the cause of cutaneous malignant melanoma type 2 (CMM2) [MIM:155601]. Malignant melanoma is a malignant neoplasm of melanocytes, arising de novo or from a pre-existing benign nevus, which occurs most often in the skin but also may involve other sites. 
Defects in CDKN2A are the cause of familial atypical multiple mole melanoma-pancreatic carcinoma syndrome (FAMMMPC) [MIM:606719]. 
Defects in CDKN2A are a cause of Li-Fraumeni syndrome (LFS) [MIM:151623]. LFS is a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53. [DISEASE] Defects in CDKN2A are the cause of melanoma-astrocytoma syndrome (MASTS) [MIM:155755]. The melanoma-astrocytoma syndrome is characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma.

Similarity:
Belongs to the CDKN2 cyclin-dependent kinase inhibitor family. 
Contains 4 ANK repeats.

Database links:

Entrez Gene: 1029 Human

Omim: 600160 Human

SwissProt: P42771 Human

Unigene: 512599 Human

 



Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications
   

该基因产生几个转录变体，它们的第一外显子不同。据报道，至少有三种编码不同蛋白的选择性剪接变异体，其中两种编码结构相关的异构体，已知其作为CDK4激酶抑制剂。其余的转录本包括一个位于基因其余部分上游20Kb的备选的第一外显子；该转录本包含一个备选的开放阅读框架（ARF），该框架指定一种结构上与其他变体的产物无关的蛋白质。这个ARF产物作为肿瘤抑制蛋白p53的稳定剂起作用，因为它可以与E3泛素-蛋白连接酶MDM2相互作用，并且隔离，MDM2是负责p53降解的蛋白质。尽管在结构和功能上存在差异，CDK抑制剂亚型和该基因编码的ARF产物通过CDK4和p53在细胞周期G1进展中的调节作用，在细胞周期G1控制中具有共同的功能。该基因在多种肿瘤中经常发生突变或缺失，是重要的抑癌基因。[ RefSeq，SEP 2012 ]提供。